In particular, patients with advanced fibrosis (F3) or cirrhosis (F4), have a substantial residual risk of HCC that remains after viral eradication.

Our study compared liver disease progression and survival in patients with stage 3 (F3) and stage 4 (F4) fibrosis on liver biopsy.

Sep 23, 2024 · Achieving a sustained virologic response (SVR) through direct-acting antivirals for hepatitis C virus (HCV) infection significantly reduces the long-term risk of hepatocellular carcinoma (HCC), particularly in patients with advanced fibrosis (F3) or cirrhosis (F4).

For example for patients with stage F2 fibrosis the RR (95% CI) for HCC were 1.76 (0.47–6.67) for SVR versus 2.86 (1.59–5.13) for non-SVR, whereas for patients with F4 fibrosis the RRs (95% CI) increase to 4.78 (1.13–20.18) and 12.23 (6.81–21.95), respectively.

Eradication of HCV by antiviral treatment reduces but does not eliminate the risk of hepatocellular carcinoma (HCC). In particular, patients with advanced brosis (F3) or cirrhosis (F4), have a. substantial residual risk of HCC that remains after viral eradication.

However, individual patients carry a variety of risk factors that modify their HCC risk after SVR, including most importantly fibrosis stage (F3 versus F4) but also age, sex, albumin level, genotype, and components of the FIB-4 score like platelet count and AST/ALT. 16,17 A tissue-based transcriptome signature has also been shown to accurately ...

Promising strategies for estimating HCC risk include simplified scoring systems (such as fibrosis-4), liver elastography and multivariable HCC risk calculators. Such tools may enable risk stratification and individualised, risk-based surveillance …

Feb 24, 2022 · The HCC risk model. GAF criteria based on gamma‐glutamyl transpeptidase, AFP, and FIB‐4 index at any point after SVR can help identify patients at negligible risk of developing HCC who may be able to discontinue HCC surveillance. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; DAA, direct‐acting antiviral.

Feb 1, 2021 · Eradication of HCV by antiviral treatment reduces but does not eliminate the risk of hepatocellular carcinoma (HCC). In particular, patients with advanced fibrosis (F3) or cirrhosis (F4), have a substantial residual risk of HCC that remains after viral eradication.

In our cohort, the Alonso A model allows the most reliable reduction in HCC screening resulting in safely stopping life-long monitoring in about a third of F3-F4 patients achieving SVR with DAAs.